As a physician, Jeffrey Aronin usually decides on how he treats his ailing patients. For instance, he once had a child under his care that was having seizures. He had to choose between medication which was a difficult call and surgery that could have been rough, but to ensure a full recovery. Eventually, Aronin chose medication. This helped to avoid possible complications as a result of surgery. Jeffrey Aronin believes that to further his career he has to build a relationship with his patients. As a result, his patients motivated him to establish Ovations Pharmaceuticals LLC.
Jeffrey Aronin attained his bachelor’s degree from Northern Illinois University. Later on, he obtained an MBA from DePaul University. He soon started a career in the healthcare sector as a doctor. Aronin discovered that most people obtain their medication from the pharmaceutical industry. This motivated him to create Ovations Pharmaceuticals in 2000 to assist patients. He wanted his career to focus fully on drugs development and catering for patient’s needs. Aronin pharmaceutical company was going to stand out from others since its focus was to address specific problems affecting patients. He aimed at changing other people’s lives.
In 2009, Lundbeck which was a Danish company offered to buy Aronin’s pharmaceutical company for $900 million. Jeffrey Aronin remained as the CEO of Ovations Pharmaceuticals. The company continues to be successful in helping patients with rare medical conditions. All this is attributed to a physician who wanted to make a difference while treating his patients. This will help to advance the healthcare systems around the world.
Paragon biosciences continue to invest in biotech companies that focus on helping patients with unmet medical needs. Some of the companies it has assisted include Castle Creek Pharmaceuticals and Harmony Biosciences. Jeffrey Aronin success in pharmaceutical industries has attracted investors that hope to change the lives of patients with the rare condition. Paragon is in an appropriate position with other biotech companies to deliver medical solutions to patients with special needs. His foundation is at the forefront to research medical conditions and diseases that have been overlooked for long.